TANDEM Bundle
The TANDEM Bundle is a two-vial amylin + GLP-1 metabolic research stack: GLP-1SG (semaglutide) 10 mg and Cagrilintide 10 mg — at 10% off the individual vial prices.
Semaglutide is a long-acting GLP-1 receptor agonist that produced substantial weight reduction in the STEP 1 randomised trial[2]. Cagrilintide is a long-acting amylin analogue evaluated in a randomised phase 2 weight-management trial[5]. Their co-administration was itself evaluated in a randomised clinical trial[6] — a documented dual-pathway model of satiety research.
Each vial is supplied as a lyophilized powder for reconstitution, and each compound has its own lot-specific third-party certificate of analysis, available on request. Findings above come from clinical research on these molecules and are provided as scientific reference for laboratory research only.
Couldn't load pickup availability
Out of stock — get notified
Leave your email and we’ll let you know the moment it’s available again.
Need reconstitution solution? Don’t forget to add Bacteriostatic Water before checkout.
Amylin + GLP-1 Research Stack
Two Vials, One Research Focus
The TANDEM Bundle pairs the two halves of one of the most studied duos in metabolic research. GLP-1SG is our listing of semaglutide, a GLP-1 receptor agonist whose molecular design was described in the peptide-engineering literature[1]. Cagrilintide is a long-acting amylin analogue developed for once-weekly administration in clinical research[4]. Unlike most research pairings, this one has been studied together: co-administered cagrilintide and semaglutide were evaluated in a randomised clinical trial[6].
- Two complementary satiety-signalling pathways
- GLP-1SG — semaglutide, GLP-1 receptor agonist
- Cagrilintide — long-acting amylin analogue
- Co-administration itself studied in clinical research
- Lot-specific third-party COA for each compound
Inside the Bundle
What's in the Stack
The bundle ships as two separate lyophilized vials: GLP-1SG (semaglutide) 10 mg and Cagrilintide 10 mg. The two molecules act on different receptor families: semaglutide on the GLP-1 receptor — with efficacy characterised in the SUSTAIN 1 randomised trial[3] — and cagrilintide on amylin (calcitonin-family) receptors — with dose-response characterised in a phase 2 dose-finding trial[5].
- GLP-1SG (semaglutide) — 10 mg lyophilized vial
- Cagrilintide — 10 mg lyophilized vial
- Incretin + amylin receptor coverage in one set
- 10% saving versus buying the two vials separately
Research Applications
Areas of Scientific Investigation
Both compounds carry extensive published evidence: in the STEP 1 trial, once-weekly semaglutide produced substantial weight reduction in adults with overweight or obesity[2]; once-weekly cagrilintide was evaluated for weight management in a randomised phase 2 trial[5]; and their co-administration was evaluated in a randomised clinical trial in adults with overweight or obesity[6].
- Incretin-receptor and satiety-signalling research
- Amylin and calcitonin-receptor pharmacology
- Appetite-regulation and energy-balance models
- Dual-pathway co-administration research
Understanding the Tandem Stack: Mechanism of Action
Semaglutide (GLP-1SG) is a long-acting analogue of glucagon-like peptide-1. Its design — albumin-binding fatty-acid side chain and dipeptidyl-peptidase-4 protection — was described in the discovery literature[1]. In randomised clinical trials it produced substantial weight reduction in adults with overweight or obesity (STEP 1)[2] and improved glycaemic control in type 2 diabetes (SUSTAIN 1)[3].
Cagrilintide is a long-acting amylin analogue: it engages amylin and calcitonin receptors, a satiety pathway distinct from the incretin axis. Its medicinal-chemistry development was described in 2021[4], and once-weekly cagrilintide was evaluated for weight management in a randomised, placebo- and active-controlled phase 2 trial[5].
What makes this pairing unusual in research catalogues: the combination itself has been studied. Co-administered cagrilintide and semaglutide were evaluated in a randomised clinical trial in adults with overweight or obesity[6], making the amylin + GLP-1 duo a documented model of dual-pathway satiety research.
Together, the two vials give researchers the two halves of that documented duo: incretin-receptor signalling (semaglutide) and amylin-receptor signalling (cagrilintide), each supported by its own line of published evidence. These materials are supplied strictly for laboratory research use.
Scientific Literature
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5(4):251-260.
- Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194.
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647.
Packaged with care, shipped fast.
We’re a passionate team obsessed with quality, not margins.
- Company
- Price
- Purity
- Quantity
- Shipping
-
TANDEM Bundle
-
Prime
Lab PeptidesTypical
Competitor -
$216.00$390.00
- ≥99%96%
- 2 vials2 vials
- Free 2-Day Shipping3-10 Business Day
-
